| Literature DB >> 35266121 |
Barbara E Jones1,2, Jian Ying3, Mckenna R Nevers4, Patrick R Alba4,5, Olga V Patterson4,5, Kelly S Peterson4,6, Elizabeth Rutter4,7, Matthew A Christensen8, Sarah Stern9,4, Makoto M Jones4,3, Adi Gundlapalli4,3, Nathan C Dean9, Matthew C Samore4,3, Tome Greene10.
Abstract
BACKGROUND: Deaths from pneumonia were decreasing globally prior to the COVID-19 pandemic, but it is unclear whether this was due to changes in patient populations, illness severity, diagnosis, hospitalization thresholds, or treatment. Using clinical data from the electronic health record among a national cohort of patients initially diagnosed with pneumonia, we examined temporal trends in severity of illness, hospitalization, and short- and long-term deaths.Entities:
Keywords: emergency department; hospitalization; outcomes; pneumonia; trends
Year: 2022 PMID: 35266121 PMCID: PMC8906522 DOI: 10.1007/s11606-022-07413-8
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 5.128
Figure 2Observed versus predicted 30-day mortality by three different models trained on early years (2006–2007—panel A) and later years (2015–2016—panel B). Complete model using all 69 patient factors (gray line); physiologic model using age, sex, vitals, and laboratory results (black dotted line); and comorbidity model using age, sex, and baseline patient demographics and comorbidities (gray dotted line). Observed 30-day mortality is represented as a black line.
Figure 3Observed trends in 30-day, 90-day, and 1-year mortality and hospitalization (solid line) versus predicted trends in same outcomes based on the complete model using all patient features trained on early years (2006–2007—dotted line) and later years (2015–2016—dashed line).
Figure 1Study population.
Patient Characteristics Overall, During Years 2006–2007, and During Years 2015–2016. Comorbidities with >2% Change or Notable Stability and Most Commonly Used Physiologic Measures Shown. For Complete List of Patient Characteristics, Please See Appendix B. Frequency (Percent Confidence Intervals) and Median (Confidence Intervals) Are Shown
| All patients | Year 2006–07: | Year 2015–16: | ||
|---|---|---|---|---|
| Demographics | ||||
| Age | 68 (68, 69) | 68 (67, 68) | 69 (69, 69 | |
| Male gender | 188,522 (96–96%) | 21997 (96–97%) | 44333 (95–95%) | |
| Married | 8,9050 (45–45%) | 10502 (43.5%, 45%) | 21140 (45%) | |
| Homelessness | 1,0905 (5.4–5.6%) | 1658 (3.1–3.6%) | 3513 (7.3–7.8%) | |
| Nursing home resident | 3,398 (1.7–1.8%) | 393 (1.4–1.8%) | 775 (1.5–1.8%) | |
| Comorbidities* | ||||
| Diabetes without complications | 6,0721 (31–31%) | 4630 (26–28%) | 15214 (32–33%) | |
| Diabetes with complications | 2,0957 (10–11%) | 1308 (7–8%) | 7194 (15–16%) | |
| Renal disease | 2,7610 (14–14%) | 1778 (10–11%) | 7482 (16–16%) | |
| Coronary artery disease | 4,5915 (23–24%) | 3503 (20–21%) | 11988 (25–26%) | |
| Congestive heart failure | 34,770 (18–18%) | 2790 (16–17%) | 8559 (18–19%) | |
| Myocardial infarction | 5,1304 (26–26%) | 4372 (25–26%) | 11822 (25–26%) | |
| Chronic obstructive pulmonary disease | 7,7968 (39–40%) | 6828 (39–40%) | 18383 (39–40%) | |
| Tobacco use disorders | 4,6332 (23–24%) | 3578 (20–21%) | 10774 (23–24%) | |
| Mood disorders | 50,064 (25–26%) | 3443 (19–21%) | 12592 (27–27%) | |
| Anxiety | 38,194 (19–20%) | 2426 (14–15%) | 10707 (23–23%) | |
| Delirium disorders | 20,785 (10–11%) | 1478 (8–9%) | 5598 (12–12%) | |
| Physiologic measures | % missing | |||
| Temperature (°F) | 3.4 | 98.7 (98.7–98.7) | 98.9 (98.9–98.9) | 98.6 (98.6–98.6) |
| Pulse (beats/min) | 2.8 | 92.7 (92.6, 92.7) | 94.4 (94.1, 94.7) | 91.9 (91.8, 92.1) |
| Respiration rate (breaths/min) | 3.1 | 20.4 (20.3, 20.4) | 21.3 (21.3, 21.4) | 19.8 (19.8, 19.9) |
| Systolic blood pressure (mmHg) | 2.9 | 132.4 (132.3, 132.5) | 130.3 (129.9, 130.7) | 134.3 (134, 134.5) |
| Pulse oximetry (%) | 15 | 93.6 (93.6, 93.7) | 93.3 (93.3, 93.4) | 93.8 (93.8, 93.9) |
| PaO2 (mmHg) | 78.7 | 73.9 (73.5, 74.2) | 71.4 (70.4, 72.4) | 75.1 (74.3, 75.9) |
| Arterial pH | 78 | 7.4 (7.4, 7.4) | 7.4 (7.4, 7.4) | 7.4 (7.4, 7.4) |
| Blood urea nitrogen (mg/dL) | 8.7 | 23.3 (23.2, 23.4) | 24.1 (23.8, 24.3) | 22.7 (22.5, 22.8) |
| Creatinine (mg/dL) | 8.3 | 1.4 (1.4, 1.4) | 1.5 (1.5, 1.5) | 1.4 (1.4, 1.4) |
| C-reactive peptide (mg/dL) | 97.2 | 92.3 (89.7, 94.9) | 136.9 (117, 156.9) | 82.3 (78, 86.6) |
| Lactic acid (mmol/L) | 78.7 | 2 (2, 2) | 2.3 (2.2, 2.4) | 1.9 (1.9, 1.9) |
| Bilirubin (mg/dL) | 28.7 | 0.9 (0.9, 0.9) | 0.9 (0.9, 1) | 0.9 (0.9, 0.9) |
| Albumin (g/L) | 29 | 3.4 (3.4, 3.4) | 3.4 (3.4, 3.4) | 3.4 (3.4, 3.5) |
| Glucose (mg/dL) | 8.1 | 139.4 (139, 139.7) | 139.8 (138.8, 140.9) | 139.9 (139.2, 140.5) |
| Platelet count (K/μL) | 8.7 | 237.3 (236.8, 237.8) | 264.9 (263, 266.8) | 232.3 (231.3, 233.3) |
| White blood cell (K/μL) | 8 | 11.9 (11.8, 11.9) | 12.6 (12.5, 12.7) | 11.5 (11.4, 11.5) |
| Systemic inflammatory response syndrome (SIRS)* | 87,738 (44–45%) | 9249 (53–54.4%) | 18228 (39–40) | |
| Outcomes | ||||
| 30-day mortality | 15,574 (7.8–8%) | 1659 (9.2–10%) | 3229 (6.7–7.2%) | |
| 90-day mortality | 27,192 (14–14%) | 2818 (16–17%) | 5751 (12–13%) | |
| 1-year mortality | 50,718 (26–26%) | 4999 (28–30%) | 11117 (24–24%) | |
| Hospitalization | 131,307 (67–67%) | 12167 (70–71%) | 29233 (62–63%) | |
| 7-day secondary hospitalization (among outpatients) | 4,919 (7.3%, 7.7%) | 405 (7.3–8.8%) | 1165 (6.3–7.1%) | |
| ICU admission (among inpatients) | 19433 (14.6%, 15%) | 1812 (14.2%, 15.5%) | 4268 (14.2%, 15%) | |
*SIRS, systemic inflammatory response syndrome[27] with the exception of mental status changes. Patients deemed to have SIRS if any two of the criteria were met: temperature > 100.4°F (38°C), pulse > 90 bpm, respiratory rate > 20 bpm, white blood cell count > 12 or < 4 K/μL
Model-Predicted Outcomes and Estimated Proportion of Change Explained by Patient Characteristics
| Outcome and Model | Probability of outcome predicted by 2006–2007 model | Probability of outcome predicted by 2015–2016 model | Percent of change explained by patient characteristics* | |||
|---|---|---|---|---|---|---|
| Year | Year | |||||
| 2006 | 2016 | 2006 | 2016 | 2006–2007 model | 2015–2016 model | |
| 30-day mortality | ||||||
| Observed | 9.6% | 7.2% | 9.6% | 7.2% | ||
| Complete model | 9.7% | 8.4% | 8.2% | 6.9% | 47% | 45% |
| Physiologic model | 9.7% | 8.4% | 8.0% | 6.9% | 44% | 39% |
| Comorbidity model | 9.5% | 10.4% | 6.2% | 7.0% | −35% | −30% |
| 90-day mortality | ||||||
| Observed | 16.4% | 12.3% | 16.4% | 12.3% | ||
| Complete model | 16.5% | 15.1% | 13.7% | 12.2% | 32% | 34% |
| Physiologic model | 16.7% | 13.7% | 14.0% | 12.3% | 68% | 39% |
| Comorbidity model | 16.3% | 17.2% | 11.7% | 12.8% | −28% | −32% |
| 1-year mortality | ||||||
| Observed | 29.0% | 23.8% | 29.0% | 23.8% | ||
| Complete model | 29.1% | 28.1% | 24.7% | 23.6% | 17% | 19% |
| Physiologic model | 29.2% | 27.5% | 25.4% | 23.7% | 31% | 31% |
| Comorbidity model | 28.8% | 31.0% | 21.3% | 23.7% | −44% | −47% |
| Hospitalization | ||||||
| Observed | 70.6% | 62.7% | 70.6% | 62.7% | ||
| Complete model | 71.0% | 69.2% | 65.1% | 62.5% | 21% | 31% |
| Physiologic model | 71.1% | 68.6% | 65.6% | 62.6% | 29% | 36% |
| Comorbidity model | 62.6% | 62.8% | 61.0% | 62.6% | −12% | −79% |
*Negative values denote that the model predicted an increase in the outcome